Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States.

Buka SL, Wallin MT, Culpepper WJ, Lee YH, Marrie RA, Nelson LM, Kaye WE, Wagner L, Tremlett H, Campbell J, LaRocca N.

Neuroepidemiology. 2020 Jan 28:1-8. doi: 10.1159/000504050. [Epub ahead of print]

PMID:
31991409
2.

Conducting dietary intervention trials in people with multiple sclerosis: Lessons learned and a path forward.

Fitzgerald KC, Sand IK, Senders A, Spain R, Giesser B, Sullivan P, Baer DJ, LaRocca N, Zackowski K, Mowry EM.

Mult Scler Relat Disord. 2019 Oct 29;37:101478. doi: 10.1016/j.msard.2019.101478. [Epub ahead of print] Review.

PMID:
31704546
3.

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.

Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS, Jacobs A, Kapoor R, Matthews PM, Mowry EM, Balcer LJ, Panzara M, Phillips G, Uitdehaag BMJ, Cohen JA; Multiple Sclerosis Outcome Assessments Consortium.

Neurology. 2019 Nov 19;93(21):e1921-e1931. doi: 10.1212/WNL.0000000000008519. Epub 2019 Oct 22.

4.

Computerized neuropsychological assessment devices in multiple sclerosis: A systematic review.

Wojcik CM, Beier M, Costello K, DeLuca J, Feinstein A, Goverover Y, Gudesblatt M, Jaworski M 3rd, Kalb R, Kostich L, LaRocca NG, Rodgers JD, Benedict RH; National MS Society Cognition Work Team.

Mult Scler. 2019 Dec;25(14):1848-1869. doi: 10.1177/1352458519879094. Epub 2019 Oct 22.

5.

Validation of an algorithm for identifying MS cases in administrative health claims datasets.

Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, Kaye WE, Wagner L, Tremlett H, Chen LH, Leung S, Evans C, Yao S, LaRocca NG; United States Multiple Sclerosis Prevalence Workgroup (MSPWG).

Neurology. 2019 Mar 5;92(10):e1016-e1028. doi: 10.1212/WNL.0000000000007043. Epub 2019 Feb 15.

6.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15. Erratum in: Neurology. 2019 Oct 8;93(15):688.

7.

A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Nelson LM, Wallin MT, Marrie RA, Culpepper WJ, Langer-Gould A, Campbell J, Buka S, Tremlett H, Cutter G, Kaye W, Wagner L, Larocca NG; United States Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):469-480. doi: 10.1212/WNL.0000000000007044. Epub 2019 Feb 15. Review.

8.

Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.

Strober L, DeLuca J, Benedict RH, Jacobs A, Cohen JA, Chiaravalloti N, Hudson LD, Rudick RA, LaRocca NG; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2019 Nov;25(13):1781-1790. doi: 10.1177/1352458518808204. Epub 2018 Oct 18.

9.

Recommendations for cognitive screening and management in multiple sclerosis care.

Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, Gingold J, Goverover Y, Halper J, Harris C, Kostich L, Krupp L, Lathi E, LaRocca N, Thrower B, DeLuca J.

Mult Scler. 2018 Nov;24(13):1665-1680. doi: 10.1177/1352458518803785. Epub 2018 Oct 10. Review.

10.
11.

Projecting the Adequacy of the Multiple Sclerosis Neurologist Workforce.

Halpern MT, Kane H, Teixeira-Poit S, Ford C, Giesser B, Halper J, Johnson S, LaRocca NG, Miller A, Ringel SP.

Int J MS Care. 2018 Jan-Feb;20(1):35-43. doi: 10.7224/1537-2073.2016-044.

12.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Review.

13.

Polyethylene cellulose nanofibrils nanocomposites.

Maia THS, Larocca NM, Beatrice CAG, de Menezes AJ, de Freitas Siqueira G, Pessan LA, Dufresne A, França MP, de Almeida Lucas A.

Carbohydr Polym. 2017 Oct 1;173:50-56. doi: 10.1016/j.carbpol.2017.05.089. Epub 2017 May 29.

14.

Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.

Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, Phillips G, LaRocca N, Hudson L, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):734-747. doi: 10.1177/1352458517690822. Epub 2017 Feb 16. Review.

15.

Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis.

Motl RW, Cohen JA, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):704-710. doi: 10.1177/1352458517690823. Epub 2017 Feb 16.

16.

Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis.

Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):721-733. doi: 10.1177/1352458517690821. Epub 2017 Feb 16.

17.

The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.

Feys P, Lamers I, Francis G, Benedict R, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium.

Mult Scler. 2017 Apr;23(5):711-720. doi: 10.1177/1352458517690824. Epub 2017 Feb 16.

18.

Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.

Motl RW, Mowry EM, Ehde DM, LaRocca NG, Smith KE, Costello K, Shinto L, Ng AV, Sullivan AB, Giesser B, McCully KK, Fernhall B, Bishop M, Plow M, Casaccia P, Chiaravalloti ND.

Mult Scler. 2018 Mar;24(3):262-267. doi: 10.1177/1352458516687404. Epub 2017 Jan 12.

19.

Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan.

Rudick RA, Larocca N, Hudson LD; MSOAC.

Mult Scler. 2014 Jan;20(1):12-7. doi: 10.1177/1352458513503392. Epub 2013 Sep 20. Review.

PMID:
24057430
20.

Beta 2 adrenergic receptor polymorphisms, at codons 16 and 27, and bronchodilator responses in adult Venezuelan asthmatic patients.

Larocca N, Moreno D, Garmendia JV, Velasquez O, Martin-Rojo J, Talamo C, Garcia A, De Sanctis JB.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Dec;157(4):374-8. doi: 10.5507/bp.2012.084. Epub 2012 Nov 2.

21.

Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.

Ontaneda D, LaRocca N, Coetzee T, Rudick R; NMSS MSFC Task Force.

Mult Scler. 2012 Aug;18(8):1074-80. doi: 10.1177/1352458512451512. Epub 2012 Jun 27.

PMID:
22740488
22.

Role of beta2 agonists in respiratory medicine with particular attention to novel patents and effects on endocrine system and immune response.

Larocca NE, Moreno D, Garmendia JV, De Sanctis JB.

Recent Pat Endocr Metab Immune Drug Discov. 2011 Sep;5(3):230-6. Review.

PMID:
21913882
23.

Inhibitors of phosphoinositol 3 kinase and NFκB for the treatment of chronic obstructive pulmonary disease.

Larocca NE, Moreno D, Garmendia JV, De Sanctis JB.

Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):178-83. Review.

PMID:
21827398
24.

Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners.

Larocca NG.

Patient. 2011;4(3):189-201. doi: 10.2165/11591150-000000000-00000.

PMID:
21766914
25.

New pharmacological treatments for patients with chronic obstructive pulmonary disease (COPD).

Larocca NE, Moreno D, Garmendia JV, De Sanctis JB.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Mar;155(1):43-50. Review.

26.

Pharmacological modulation of Th17.

De Sanctis JB, Garmendia JV, Moreno D, Larocca N, Mijares M, Di Giulio C, Salazar-Bookaman M, Wojewodka G, Radzioch D.

Recent Pat Inflamm Allergy Drug Discov. 2009 Jun;3(2):149-56.

PMID:
19519592
27.

Preface: Perspectives of an MS Researcher.

Larocca NG.

Occup Ther Health Care. 2004;17(3-4):xix-xx. doi: 10.1080/J003v17n03_b. No abstract available.

PMID:
23941227
28.

Minimal neuropsychological assessment of MS patients: a consensus approach.

Benedict RH, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, Chelune GJ, Fisk JD, Langdon DW, Caruso L, Foley F, LaRocca NG, Vowels L, Weinstein A, DeLuca J, Rao SM, Munschauer F.

Clin Neuropsychol. 2002 Aug;16(3):381-97. Review.

PMID:
12607150
29.

Determinants of health-related quality of life in multiple sderosis: the role of illness intrusiveness.

Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV.

Mult Scler. 2002 Aug;8(4):310-8.

PMID:
12166502
30.

Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis.

Foley FW, LaRocca NG, Sanders AS, Zemon V.

Mult Scler. 2001 Dec;7(6):417-21.

PMID:
11795465
31.

Recent developments in the assessment of quality of life in multiple sclerosis (MS).

Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D.

Mult Scler. 1999 Aug;5(4):251-9. Review.

PMID:
10467384
32.

Utilization of unconventional treatments by persons with MS: is it alternative or complementary?

Schwartz CE, Laitin E, Brotman S, LaRocca N.

Neurology. 1999 Feb;52(3):626-9.

PMID:
10025800
33.

Patient perception of quality of care provided by specialists and generalists.

Schwartz CE, Brotman S, LaRocca N, Lee H.

Mult Scler. 1998 Oct;4(5):426-32.

PMID:
9839303
34.

Helplessness, self-efficacy, cognitive distortions, and depression in multiple sclerosis and spinal cord injury.

Shnek ZM, Foley FW, LaRocca NG, Gordon WA, DeLuca J, Schwartzman HG, Halper J, Lennox S, Irvine J.

Ann Behav Med. 1997 Summer;19(3):287-94.

PMID:
9603703
35.

A program to facilitate retention of employment among persons with multiple sclerosis.

Larocca NG, Kalb RC, Gregg K.

Work. 1996;7(1):37-46. doi: 10.3233/WOR-1996-7106.

PMID:
24441620
36.

Stress, Multiple Sclerosis, and Everyday FunctioningA Review of the Literature with Implications for Intervention.

Foley FW, Larocca NG, Kalb RC, Caruso LS, Shnek Z.

NeuroRehabilitation. 1993;3(4):57-66. doi: 10.3233/NRE-1993-3409.

PMID:
24526157
37.

Psychosocial, Affective, and Behavioral Consequences of Multiple SclerosisTreatment of the "Whole" Patient.

Larocca NG, Kalb RC, Foley FW, McGann CM.

NeuroRehabilitation. 1993;3(4):30-8. doi: 10.3233/NRE-1993-3406.

PMID:
24526154
38.

Endogenous event-related potentials as indices of dementia in multiple sclerosis patients.

Giesser BS, Schroeder MM, LaRocca NG, Kurtzberg D, Ritter W, Vaughan HG, Scheinberg LC.

Electroencephalogr Clin Neurophysiol. 1992 May;82(5):320-9.

PMID:
1374701
39.

A prospective study of depression and immune dysregulation in multiple sclerosis.

Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, Scheinberg LC.

Arch Neurol. 1992 Mar;49(3):238-44.

PMID:
1536625
40.

High-dose oral baclofen: experience in patients with multiple sclerosis.

Smith CR, LaRocca NG, Giesser BS, Scheinberg LC.

Neurology. 1991 Nov;41(11):1829-31.

PMID:
1944915
41.

A study of fatigue in systemic lupus erythematosus.

Krupp LB, LaRocca NG, Muir J, Steinberg AD.

J Rheumatol. 1990 Nov;17(11):1450-2.

PMID:
2273484
42.

Guidelines for neuropsychological research in multiple sclerosis.

Peyser JM, Rao SM, LaRocca NG, Kaplan E.

Arch Neurol. 1990 Jan;47(1):94-7. Review.

PMID:
2403789
43.

Multiple sclerosis program: a model for neuropsychiatric disorders.

LaRocca NG, Hall HL.

New Dir Ment Health Serv. 1990 Spring;(45):49-64. Review. No abstract available.

PMID:
2191214
44.

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD.

Arch Neurol. 1989 Oct;46(10):1121-3.

PMID:
2803071
45.

A comparative study of impairment ratings in multiple sclerosis patients.

Holland NJ, Francabandera F, Wiesel-Levison P, Halper J, LaRocca NG, Scheinberg LC.

Rehabil Nurs. 1988 Sep-Oct;13(5):244-50. No abstract available.

PMID:
3187174
46.

Fatigue in multiple sclerosis.

Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC.

Arch Neurol. 1988 Apr;45(4):435-7.

PMID:
3355400
47.

Psychoimmunological dysregulation in multiple sclerosis.

Foley FW, Miller AH, Traugott U, LaRocca NG, Scheinberg LC, Bedell JR, Lennox SS.

Psychosomatics. 1988 Fall;29(4):398-403. No abstract available.

PMID:
2906448
48.

Efficacy of stress-inoculation training in coping with multiple sclerosis.

Foley FW, Bedell JR, LaRocca NG, Scheinberg LC, Reznikoff M.

J Consult Clin Psychol. 1987 Dec;55(6):919-22. No abstract available.

PMID:
3693660
49.

Trimodal evoked potentials compared with magnetic resonance imaging in the diagnosis of multiple sclerosis.

Giesser BS, Kurtzberg D, Vaughan HG Jr, Arezzo JC, Aisen ML, Smith CR, LaRocca NG, Scheinberg LC.

Arch Neurol. 1987 Mar;44(3):281-4.

PMID:
3827679
50.

Factors associated with unemployment of patients with multiple sclerosis.

Larocca N, Kalb R, Scheinberg L, Kendall P.

J Chronic Dis. 1985;38(2):203-10.

PMID:
3156140

Supplemental Content

Loading ...
Support Center